Con el control del Senado y la Cámara de Representantes, tendrán el poder de elegir qué propuestas de salud se votarán en el Congreso. Pero no será tan fácil.
With a majority too small to eliminate the filibuster, Democrats will not have enough votes in the Senate to pass many of their plans without Republicans and will also have only a razor-thin majority in the House. This combination could doom many Democratic health care proposals, like offering Americans a government-sponsored public insurance option, and complicate efforts to pass further pandemic relief.
The coronavirus pandemic has hit hard for Troy Muenzer of Chicago. He had a “suspected case” of COVID in the spring, was billed nearly $1,000 after he unsuccessfully sought to get tested for COVID-19 and has been furloughed after the airline he worked for saw a major decline in passengers.
Republican spokespeople for the committees responsible for vetting Health and Human Services nominations said the Senate may not hold hearings on California Attorney General Xavier Becerra, President-elect Joe Biden’s pick to lead the department, until the Senate approves committee assignments for the new Congress. That could delay the start of the process.
In a notable loss for Democrats, Shalala, who represented a Miami district, was defeated by Maria Elvira Salazar — a Republican former TV journalist who compared Democratic policy proposals to leftist oppression in countries like Cuba.
Democrats are favored to win both chambers of Congress after years of campaign-trail promises about health care. But their margin in the Senate could be slim, making it difficult to pass major health care legislation. And they still must heal some rifts within the caucus about how far they can push overhaul efforts.
Los hallazgos de una nueva encuesta indican que los votantes no confían en las garantías del presidente de que protegerá a las personas con condiciones preexistentes.
More than 50% of people said they favor Democratic presidential candidate Joe Biden’s approach to an array of health issues.
In less than six years, Sen. Joni Ernst has gone from being a rising star in the Republican Party to running neck and neck against a political newcomer. A poll last month showed more than 1 in 3 Iowa voters think Ernst’s relationship to President Donald Trump is “too close,” and her comments about the coronavirus death toll sparked a backlash.
Rural hospitals have been closing at a quickening pace in recent years, but a number of inner-city hospitals now face a similar fate. Experts fear that the economic damage inflicted by the COVID pandemic is helping push some of these urban hospitals over the edge at the very time their services are most needed.
Hospital employees say they must choose between their paychecks and their health or that of their families. Returning to work with symptoms also risks infection among the patients they are meant to heal.
Language in the CARES Act says providers who take emergency funding cannot balance-bill coronavirus patients ― and “every patient” is considered a possible COVID-19 patient.
Nadie está haciendo mucho para rescatar a pacientes que necesitan desesperadamente protección contra este tipo de facturas, en un sistema que cobra libremente por cada atención que dispensa.
Hidden costs for ER visits and other fees could cost people thousands of dollars.
Three senators on a revived subcommittee received more than $100,000 each from drugmakers.
The candidates talked about their views on how this public health crisis should be managed. Though they disagreed on many points, they shared disapproval of the Trump administration’s response.
En el debate número 10 realizado en Charleston, Carolina del Sur, también se unieron para atacar al senador por Vermont Bernie Sanders, actual favorito.
The stakes appeared higher in this debate as candidates focused on the upcoming South Carolina primary this weekend and Super Tuesday.
Candidates’ tough health policy talk strayed far from hope for unity.
A study ordered by the Food and Drug Administration failed to prove that Makena, the only drug approved to prevent premature birth, is effective. While a panel of experts has recommended withdrawing the drug’s approval, many doctors are wary.